Gynecologic Oncology Articles

Study Warns Women of Premature Discontinuation of Cervical Cancer Screening
Mary C. White, ScD, MPH, discusses the unmet needs near and after the stopping age for cervical cancer screening.
Zoptarelin Doxorubicin Falls Short in Phase III Endometrial Cancer Trial
Zoptarelin doxorubicin (Zoptrex), a hybrid molecule combining an LHRH-agonist and doxorubicin, failed to improve median overall survival in a phase III advanced endometrial cancer trial, according to the manufacturer of the treatment, Aeterna Zentaris.
Bariatric Surgery Associated With Reduced Risk for Female-specific Cancers
Women who underwent bariatric surgery to combat obesity were less likely to develop any cancer and female-specific cancers, as demonstrated in results published in Gynecologic Oncology.
Expert Addresses Issues in Advanced Gynecologic Cancers
Dana Chase, MD, discusses obstacles to progress and her hope for the future in advanced gynecologic cancers.
Minimally Invasive Surgery Increasingly Used in Gynecologic Malignancies
Shana Wingo, MD, discusses the advancements being made in the field of surgery for patients with gynecologic cancers.
Expert Discusses Challenges in Gynecologic Cancers
Shitanshu Uppal, MD, discusses the critical challenges to research and treatment advances in cervical and endometrial cancer.
Disparities in Guideline-Based Cervical Cancer Care Greatest at High-Volume Hospitals
Shitanshu Uppal, MD, discusses a study of racial and ethnic disparities in guideline-based care for women with locally advanced cervical cancer and the need for a more comprehensive registry process.
A Call for Molecular Profiling in Uterine Carcinosarcoma
Douglas Levine, MD, discusses a recent study in uterine carcinosarcoma and early steps toward developing therapeutic regimens.
Implementation of Cervical Cancer Screening in Developing Countries
Ann Marie Beddoe, MD, discusses a study implementing cervical cancer screening and highlights HPV predictors in developing countries.
Immunotherapy AXAL Tops Survival Mark in Cervical Cancer
An immunotherapy targeting HPV-infected cells led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer.
Publication Bottom Border
Border Publication